US › Healthcare

Ginkgo Bioworks Holdings (DNA)

US · Healthcare · Biotechnology

$9.37+4.81%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$19.5M
Revenue YoY
-59.7%
Net profit
$-82.6M
Profit YoY
+9.2%
EPS
$-1.39
EPS estimate
$-1.34
Net margin
-424.1%

EPS came in at -1.39 against a street estimate of -1.34 — a miss of 3.7%.

Key statistics

Market cap
$528.5M
Forward P/E
0.0
P/B
1.19
Book value
$7.19
EPS (TTM)
$-5.38
52-week high
$17.58
52-week low
$5.37
50-day MA
$8.71
200-day MA
$8.85
Beta
1.78

Analyst view

Analysts rate Ginkgo Bioworks Holdings a hold (1 buy, 1 hold, 4 sell out of 6) with an average price target of $8.50.

Shareholding

Insiders
4.60%
Institutions
69.83%

Largest institutional holders

FundStake
BlackRock Inc5.58%
Viking Global Investors LP5.48%
Vanguard Group Inc4.44%
Baillie Gifford & Co Limited.3.66%
Erste Asset Management GmbH2.98%
Vanguard Capital Management, LLC2.93%
Anchorage Advisors, LLC2.67%
Legal & General Group PLC2.54%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ginkgo Bioworks Holdings — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.